US Market News
2週前
Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)June 1, 2026 8:00 AM
ACCESS NewswireFORT LAUDERDALE, FL / ACCESS Newswire / June 1, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Rivaroxaban tablets of 2.5mg, 10mg, 15mg and 20mg for the Canadian market. Rivaroxaban is the generic equivalent of the brand name anticoagulant, Xarelto®.Rivaroxaban is a direct oral anticoagulant prescribed to treat and prevent deep vein thrombosis and pulmonary embolism. It is also widely utilized to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.The global market for Rivaroxaban is estimated to reach $12.7 Billion in 2026 and is set to expand to approximately $30.5 Billion by 2035, growing at a CAGR of 10.19% during the forecast from 2026 to 2035, (Business Research Insights). According to IQVIA Pharmafocus 2028, the Canadian pharmaceutical market accounts for approximately 2.1% of the global pharmaceutical market and ranks as the 6th largest worldwide.Sunshine Biopharma has established a robust distribution network across Canada through its wholly owned Canadian subsidiary, Nora Pharma Inc. The addition of Rivaroxaban to our portfolio of drugs represents a strategic expansion for the Company in the area of anticoagulants. The Company's first generic anticoagulant, Apixaban (brand name Eliquis®) has been on the market for over three years. It is anticipated that Sunshine Biopharma's Rivaroxaban will be ready to ship to pharmacies in October 2026."We are pleased to introduce Rivaroxaban oral tablets as the newest addition to our expanding portfolio of high-quality generic drugs," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "This approval strengthens our position in the generics market and reflects our ongoing commitment to delivering affordable medicines that patients and healthcare providers can rely on."About Sunshine Biopharma Inc.Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled to be launched in the remainder of 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.All registered trademarks are the property of their respective owners.Safe Harbor Forward-Looking StatementsThis press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.For more information, please contact:Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.comSOURCE: Sunshine Biopharma Inc.View the original press release on ACCESS NewswireOriginal: Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)
US Market News
2週前
Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment TechnologyMay 29, 2026 8:00 AM
ACCESS NewswireFORT LAUDERDALE, FL / ACCESS Newswire / May 29, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,624,066 B2, titled "Compounds and Methods for Treatment of Coronavirus Infection." The newly granted patent protects Sunshine Biopharma's proprietary therapeutic compounds designed to inhibit coronavirus replication.The patent covers a series of small molecule inhibitors discovered and developed by Sunshine Biopharma scientists during the COVID-19 pandemic. These compounds target a critical viral enzyme (PLpro) responsible for suppression of the human immune system, making Coronavirus infections life-threatening.Coronaviruses are known for their high mutation rate, a biological characteristic that has already produced multiple variants of concern since 2020. Each new mutation has the potential to alter transmissibility, disease severity, or resistance to existing treatments and vaccines. Scientific experts worldwide continue to warn that Coronavirus remains one mutation away from triggering another global health crisis.Sunshine Biopharma's patented technology is designed with this evolutionary reality in mind. By targeting a highly conserved viral function, the Company aims to develop antiviral candidates that remain effective even as the virus continues to mutate."The issuance of this patent is a major milestone for Sunshine Biopharma and a validation of our scientific strategy," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "Coronaviruses mutate rapidly, and the world cannot assume the threat has passed. Our goal is to advance therapies that can help address not only today's variants but also those that may emerge in the future."The compounds covered under U.S. Patent 12,624,066 B2 are currently ready for GLP studies which is the step necessary to be completed before entering clinical trials. Sunshine Biopharma continues to invest in research aimed at developing robust solutions to current and future viral threats.About Sunshine Biopharma Inc.Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled to be launched in the remainder of 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.Safe Harbor Forward-Looking StatementsThis press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.For more information, please contact:Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.comSOURCE: Sunshine Biopharma Inc.View the original press release on ACCESS NewswireOriginal: Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology
INV4
2週前
Agree Jus.
This stock pain in da ass INV!!! So good news a d products but sellers pounding it
=================
Stocks Under $1: NXXT, TOON, VRAX, AIM, SBFM on Breakout Watch
Investors searching for stocks under $1 with breakout potential, AI exposure, biotech catalysts, streaming growth, and emerging healthcare innovation are increasingly focusing on a group of small-cap companies gaining momentum across multiple high-growth sectors. Companies drawing attention include Kartoon Studios (NYSE: TOON), Virax Biolabs Ltd (NASDAQ: VRAX), NextNRG Inc. (NASDAQ: NXXT), AIM ImmunoTech Inc. (NYSE: AIM), and Sunshine Biopharma Inc. (NASDAQ: SBFM)...
... Meanwhile, Sunshine Biopharma (NASDAQ: SBFM) continues expanding its pharmaceutical footprint with 71 marketed generic prescription drugs in Canada and 12 additional launches planned through 2026. The company is also advancing proprietary therapeutic programs, including an mRNA-Lipid Nanoparticle candidate targeting liver cancer and a protease inhibitor focused on SARS-related coronavirus infections, strengthening its exposure to both oncology and antiviral drug development markets.
As capital continues rotating into high-growth small-cap sectors, TOON, VRAX, NXXT, AIM, and SBFM are emerging on investor watchlists due to their combination of AI integration, healthcare innovation, streaming growth, renewable energy infrastructure, and biotech catalysts.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Link article
$SBFM 🗞️
INV4
3週前
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin
May 21, 2026
FORT LAUDERDALE, FL / ACCESS Newswire / May 21, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Amoxicillin formulation for the Canadian market. This strategic expansion reinforces Sunshine Biopharma's commitment to providing affordable, high-quality antibiotics to patients across Canada.
Amoxicillin, a widely prescribed penicillin-class antibiotic, is used to treat a variety of bacterial infections including ear infections, sinus infections, strep throat, pneumonia, bronchitis, urinary tract infections, skin and soft-tissue infections, and dental infections. Sunshine Biopharma's generic version will be available in multiple dosage forms and strengths, ensuring broad accessibility for prescribers and pharmacists. It is anticipated that Sunshine Biopharma's Amoxicillin will be ready to ship to pharmacies in August 2026.
Amoxicillin global sales revenue in 2025 was estimated to be between $4.9 billion and $5.9 billion USD and is expected to increase at a compounded annual growth rate (CAGR) of 2.9% reaching approximately $6.4 USD by 2031. The major drivers for this market growth include the increasing prevalence of bacterial infections worldwide, the rising demand for affordable antibiotic treatments, and the growing adoption Amoxicillin in pediatric and adult care. The Canadian market comprises approximately 2% of the global total (IQVIA, OECD, Health Canada).
"We are proud to add Amoxicillin to our expanding portfolio of generic antibiotics," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "This launch aligns with our mission to deliver essential medications at competitive prices while maintaining the highest standards of quality and compliance."
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled to be launched in the remainder of 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For more information, please contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
Link article
$SBFM 🗞️
US Market News
3週前
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic AmoxicillinMay 21, 2026 7:00 AM
ACCESS NewswireFORT LAUDERDALE, FL / ACCESS Newswire / May 21, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Amoxicillin formulation for the Canadian market. This strategic expansion reinforces Sunshine Biopharma's commitment to providing affordable, high-quality antibiotics to patients across Canada.Amoxicillin, a widely prescribed penicillin-class antibiotic, is used to treat a variety of bacterial infections including ear infections, sinus infections, strep throat, pneumonia, bronchitis, urinary tract infections, skin and soft-tissue infections, and dental infections. Sunshine Biopharma's generic version will be available in multiple dosage forms and strengths, ensuring broad accessibility for prescribers and pharmacists. It is anticipated that Sunshine Biopharma's Amoxicillin will be ready to ship to pharmacies in August 2026.Amoxicillin global sales revenue in 2025 was estimated to be between $4.9 billion and $5.9 billion USD and is expected to increase at a compounded annual growth rate (CAGR) of 2.9% reaching approximately $6.4 USD by 2031. The major drivers for this market growth include the increasing prevalence of bacterial infections worldwide, the rising demand for affordable antibiotic treatments, and the growing adoption Amoxicillin in pediatric and adult care. The Canadian market comprises approximately 2% of the global total (IQVIA, OECD, Health Canada)."We are proud to add Amoxicillin to our expanding portfolio of generic antibiotics," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "This launch aligns with our mission to deliver essential medications at competitive prices while maintaining the highest standards of quality and compliance."About Sunshine Biopharma Inc.Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled to be launched in the remainder of 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.Safe Harbor Forward-Looking StatementsThis press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.For more information, please contact:Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.comSOURCE: Sunshine Biopharma Inc.View the original press release on ACCESS NewswireOriginal: Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin
US Market News
4週前
Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public OfferingMay 19, 2026 12:05 PM
ACCESS Newswire$6.0 million upfront with up to an additional approximately $12.0 million of potential aggregate gross proceeds upon the exercise in full of warrants.FORT LAUDERDALE, FL / ACCESS Newswire / May 19, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and developing life-saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the closing of its previously announced public offering made on a reasonable best efforts basis with gross proceeds to the Company of approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company.The offering consisted of 12,000,000 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant and (ii) two (2) Series C Warrants to purchase one (1) share of Common Stock per warrant at an initial exercise price of $0.50. The public offering price per Common Unit was $0.50 (or $0.49999 per Pre-Funded Unit, which is equal to the public offering price per Common Unit sold in the offering minus an exercise price of $0.00001 per share under the Pre-Funded Warrants). The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until exercised in full. The Series C Warrants are exercisable immediately and expire five years after the initial issuance date. The exercise price and number of shares issuable under the Series C Warrants are subject to adjustment as described in more detail in the final prospectus filed in connection with the offering.Gross proceeds to the Company were approximately $6.0 million. The potential additional gross proceeds to the Company from the Series C Warrants, if fully-exercised on a cash basis, will be approximately $12.0 million. No assurance can be given that any of warrants will be exercised. The Company expects to use the net proceeds from the offering for general corporate purposes and working capital.Aegis Capital Corp. acted as the exclusive placement agent for the offering. Sichenzia Ross Ference Carmel LLP acted as counsel to the Company. Kaufman & Canoles, P.C. acted as counsel to Aegis Capital Corp.A registration statement on Form S-1 (No. 333-295800) previously filed with the U.S. Securities and Exchange Commission (the "SEC") on May 12, 2026 was declared effective by the SEC on May 18, 2026. The offering was made only by means of a prospectus. A final prospectus describing the terms of the offering has been filed with the SEC and is available on the SEC's website located at www.sec.gov. Electronic copies of the final prospectus may be obtained by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate @RAREBREED. Before investing in this offering, interested parties should read in their entirety the prospectus, which provides more information about the Company and such offering.This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Sunshine Biopharma Inc.Sunshine Biopharma currently markets 60 generic prescription drugs in Canada, with 12 additional launches planned for the remainder of 2026. The Company is also advancing two proprietary drug development programs:K1.1 mRNA, an mRNA-Lipid Nanoparticle therapeutic candidate targeting liver cancer.PLpro protease inhibitor, a small-molecule antiviral candidate for SARS-related coronavirus infections.Additional information is available at www.sunshinebiopharma.com.Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company's product development and business prospects, the use of proceeds from the offering, and the exercise of any warrants, can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans, including the risk factors described in the Company's documents filed with the Securities and Exchange Commission. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned as a result of these risks. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.comSOURCE: Sunshine Biopharma Inc.View the original press release on ACCESS NewswireOriginal: Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering
US Market News
4週前
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public OfferingMay 18, 2026 12:15 PM
ACCESS NewswireFORT LAUDERDALE, FL / ACCESS Newswire / May 18, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and developing life-saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company.The offering consisted of 12,000,000 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant and (ii) two (2) Series C Warrants to purchase one (1) share of Common Stock per warrant at an initial exercise price of $0.50. The public offering price per Common Unit is $0.50 (or $0.49999 per Pre-Funded Unit, which is equal to the public offering price per Common Unit minus an exercise price of $0.00001 per share under the Pre-Funded Warrants). The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full. The Series C Warrants will be exercisable immediately and expire five years after the initial issuance date. The exercise price and number of shares issuable under the Series C Warrants are subject to adjustment as described in more detail in the final prospectus to be filed in connection with the offering.The transaction is expected to close on or about May 19, 2026, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering for general corporate purposes and working capital.Aegis Capital Corp. is acting as the exclusive placement agent for the offering. Sichenzia Ross Ference Carmel LLP is acting as counsel to the Company. Kaufman & Canoles, P.C. is acting as counsel to Aegis Capital Corp.A registration statement on Form S-1 (No. 333-295800) previously filed with the U.S. Securities and Exchange Commission (the "SEC") on May 12, 2026 was declared effective by the SEC on May 18, 2026. The offering is being made only by means of a prospectus. A final prospectus describing the terms of the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Electronic copies of the final prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate @RAREBREED. Before investing in this offering, interested parties should read in their entirety the prospectus, which provides more information about the Company and such offering.This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Sunshine Biopharma Inc.Sunshine Biopharma currently markets 60 generic prescription drugs in Canada, with 12 additional launches planned for the remainder of 2026. The Company is also advancing two proprietary drug development programs:K1.1 mRNA, an mRNA-Lipid Nanoparticle therapeutic candidate targeting liver cancer.PLpro protease inhibitor, a small-molecule antiviral candidate for SARS-related coronavirus infections.Additional information is available at www.sunshinebiopharma.com.Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company's product development and business prospects, the closing of the offering, and the use of proceeds from the offering, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans, including the risk factors described in the Company's documents filed with the Securities and Exchange Commission. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned as a result of these risks. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.comSOURCE: Sunshine Biopharma Inc.View the original press release on ACCESS NewswireOriginal: Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
US Market News
2月前
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior YearApril 6, 2026 8:30 AM
ACCESS NewswireFORT LAUDERDALE, FL / ACCESS Newswire / April 6, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ("Sunshine Biopharma" or the "Company"), a pharmaceutical company offering and developing life-saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.2025 HighlightsRevenue of $36.3 million, representing a 4.1% increase compared to 2024.$2.46 million in gross proceeds raised through a registered direct offering to support expansion of sales operations.Nine new generic prescription drugs launched, expanding the Company's portfolio in oncology, cardiovascular health, central nervous system disorders, and antimicrobials.Advancement of proprietary antiviral research, including a new series of orally active, non-covalent PLpro protease inhibitors that demonstrated dose-dependent antiviral activity in SARS-CoV-2-infected mice, strong potency in cellular models, and favorable pharmacokinetics.Management Commentary"We are pleased with our accomplishments in 2025, as we remain committed to reaching profitability in the near future," said Dr. Steve Slilaty, CEO. "Looking ahead, we are excited about the opportunities for growth in 2026 and beyond as we continue expanding our generic drug portfolio and advancing our proprietary drug development programs to deliver more life-saving medicines to the market."Financial Summary (in millions) 20252024Revenue$36.31$34.87Gross Profit$12.26$10.67General & Administrative Expenses$18.48$16.48Net Loss$5.98$5.13The increase in General & Administrative Expenses in 2025 was primarily driven by a non-cash, non-recurring impairment charge of $1.75 million related to intangible assets. Excluding this charge, the Company's operating performance reflects a meaningful improvement over 2024.In January 2026, Sunshine Biopharma implemented cost-reduction initiatives aimed at lowering general and administrative expenses and sharpening the Company's focus on achieving near-term profitability. Based on current plans, these initiatives are expected to reduce expenses by approximately $2 million to $3 million in 2026, although there can be no assurance that these reductions will be fully realized.About Sunshine BiopharmaSunshine Biopharma currently markets 71 generic prescription drugs in Canada, with 12 additional launches planned for the remainder of 2026. The Company is also advancing two proprietary drug development programs:K1.1 mRNA, an mRNA-Lipid Nanoparticle therapeutic candidate targeting liver cancer.PLpro protease inhibitor, a small-molecule antiviral candidate for SARS-related coronavirus infections.Additional information is available at www.sunshinebiopharma.com.Forward-Looking StatementsThis press release contains forward-looking statements based on current expectations, forecasts, and assumptions that involve risks and uncertainties. These statements include, but are not limited to, those regarding the Company's financial performance, drug development activities, and future growth opportunities. Actual results may differ materially due to various risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission. Readers are encouraged to review the Company's most recent SEC filings for additional information.Contact:Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.comSOURCE: Sunshine Biopharma Inc.View the original press release on ACCESS NewswireOriginal: Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
Dragon Lady
5月前
$SBFM : BRETT and DEBORAH ROSEN CRIMINAL INDICTED !
This POS was another BRETT ROSEN dirt ticker special.....yepper....well....his days are over....:))
https://finance.yahoo.com/news/sunshine-biopharma-receives-0-9-130000806.html
Bet this POS ticker ain't so "delighted" now LMAO.....!!!
Aka RB Capital ....one of the worst gutter toxic death spiral lenders to ever walk the earth....dirt ticker $OPTI....aka COVID FRAUD with DIRTY ROGER PAWSON...was his biggest criminal scam he ever ran.....!!!
💀 ☠️ 💀 ☠️ 💀 ☠️
Where's Brett??
Well.....FINALLY....it happened LOL !!
Man....I put a TON of "work" in.... behind on the scenes on POS Rosen aka DIRTY BRETT...and OPTEC...sent bazillions of documents and briefs etc to the SEC and "other" 3-Ltr agencies....
The GOLDEN BREAK....was the Sharp deposition videos....where hyped on coke Rosen....said "EVERYONE knows those convertibles....they ALWAYS change from whatever the hell is in the PR and the contract ....we ALWAYS dump far more than whatever crap OTC filings says...like who doesn't know that already" blah blah....THANKS DIRTY BRETT for self incrimination....at a criminal level.....
Here it is....in all it's great glory....you Td....you worked this one hard too....and deserve credit for another bust-down....this is a biggy....BIG BIG BIG ...good work :))
https://www.justice.gov/usao-sdca/pr/la-jolla-based-couple-charged-100-million-fraud?bm-verify=AAQAAAAM_____49VeyhqTqNpkGFcW7lBgg2K6dBA8v-QB57X0dYotZIf5HIoNyw_E4uD_zcuwanA0t9kd0Q3NVm43tb7e7BmgDL-aj7tab_HhSDOd67l32T-V0BtuVRb484XyGPamMcpK4_VlMXcXZ7QzBfMfRiYf5FSHQzeC8CHNa1rHw1-Ml98Q9dXseKQcT7dQQAPIX4JKcWyJOPp_lR8Fu-xRXwH4YI3VST8TI5cUyVtPwBAxtwLXDQVYZdt-sNUHXBq7vaSDRxkqCQA4cwHf5tx1KGmRrYxhwd4B8yNyiL3NFJaexF4fkfzCUnydPv7js8MzgHvZK9LpJJlH4EgC9BAAMWFfEtlHaKNnNwJiA
La Jolla-Based Couple Charged with $100 Million Fraud
Wednesday, January 21, 2026
SAN DIEGO – Brett Rosen and Deborah Rosen of La Jolla were indicted by a federal grand jury on charges that they, through their joint investment business, RB Capital Partners, Inc., engaged in a years-long securities fraud and money laundering scheme.
According to the 24-count indictment, since 2020, the Rosens engaged in a market manipulation scheme through financing, promoting, and selling the stock of six publicly traded companies – Optec International, Inc., Sunshine Biopharma, Inc., BlockQuarry Corp., Solar Integrated Roofing Corp., Cyberlux Corp., and Ilustrato Pictures International, Inc.
The indictment alleges that the Rosens’ promotions of these companies provided false and misleading information to investors, potential investors, and the market about their financing of and stock positions in these companies. The false and misleading information was designed to encourage the public to invest in these companies while the Rosens secretly dumped their own stock in these companies to make millions of dollars.
According to the indictment and court documents, the Rosens used the profits of their massive securities fraud scheme to fund their lofty lifestyle, including to purchase a multi-million dollar home in La Jolla Shores.
The United States acknowledges the assistance and cooperation of the Securities and Exchange Commission and the Criminal Prosecution Assistance Group of the Financial Industry Regulatory Authority.
This case is being prosecuted by Assistant U.S. Attorneys Janaki G. Chopra and Joseph S. Smith.
DEFENDANTS Case Number 26-CR-0192-DMS
Brett David Rosen Age: 45 La Jolla, CA
Deborah Rachel Rosen Age: 44 La Jolla, CA
RB Capital Partners, Inc. La Jolla, CA
CHARGES
Conspiracy, in violation of 18 U.S.C. § 371
Maximum Penalties: Five years in prison; $250,000 fine
Securities Fraud, in violation of 15 U.S.C. §§ 78(b), 78ff & 17 C.F.R. §. 240.10b-5
Maximum Penalties: Twenty years in prison; $5 million fine
Conspiracy to Launder Monetary Instruments, in violation of 18 U.S.C. § 1956(h)
Maximum Penalties: Twenty years in prison; $500,000 fine or twice the amount of the criminally derived property involved in the transaction
Money Laundering, in violation of 18 U.S.C. § 1957
Maximum Penalties: Ten years in prison; $250,000 fine
INVESTIGATING AGENCIES
Federal Bureau of Investigation
*The charges and allegations contained in an indictment are merely accusations, and the defendants are considered innocent unless and until proven guilty.
Contact
Kelly Thornton, Director of Media Relations
Updated January 21, 2026
ANY wonder now....why the dude dropped off the face of the earth LMAO.....AND rented out is bullshit "2nd home...but that's just my office" blah blah....AND would not reveal his real $7 mil crib address....the one that took me like about 1.3 minutes to find using freaking Google and public filings going back years....
DIRTY BRETT ROSEN....OPTEC...now a criminal scam....AND....every other dirt ticker the dude ever hustled......
He's looking at CLUB FED PRISON....and...best part....that filthy wifey of his is going "down" too....just not the way she's used to "going down"....welcome to the PRISON "GIRL'S CLUB " card membership ....it's free...courtesy of Uncle Sam R US....:))
Several counts are "up to 20 years federal prison"....several others are "up to 10 years"..... EVEN on a decent plea deal...this POS is going to likely "do" approx 5 years in a CLUB FED lockdown....couldn't happen to a nicer POS LOL !!!
CRIMINALLY INDICTED....January 21 2026....a day of infamy in PENNY STOCK OTC DIRTY HISTORY......!!!
georgie18
7月前
SBFM...$1.84...🥳...The $1.65 dip in the A/H looking better here...
georgie18
Member Level
Re: georgie18 post# 400206
Tuesday, October 28, 2025 6:05:30 PM
Post#
400237
of 400243
SBFM...$1.61...🥳...Added a load of $1.65 range to my $1.95 shares...
georgie18
Member Level
Re: georgie18 post# 703763
Tuesday, October 28, 2025 10:24:17 AM
Post#
703799
of 703927
SBFM...Back in at $1.95...🥳
georgie18
Member Level
Re: georgie18 post# 400189
Tuesday, October 28, 2025 8:10:04 AM
Post#
400191
of 400205
SBFM...$2.26...🥳
georgie18
Member Level
Re: Strukture post# 703415
Tuesday, October 28, 2025 7:59:41 AM
Post#
703760
of 703760
SBFM...$1.98...🥳... https://finviz.com/news/206655/sunshine-biopharma-gains-fda-equivalent-clearance-in-canada-for-domperidone-to-treat-cancer-related-nausea
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
The GidDy uP Kid
2週前
glenn1919
2週前
JusDePomme
2週前
Homebrew
5月前
Strukture
8月前
kingbee
8月前
AKATITUS
8月前
nowwhat2
8月前
メールアドレスで登録
